Deal Flow
Letter · prints on one page
Transaction tear sheetData as of Nov 7, 2026
M&A · Healthcare · Wholesale-Medical, Dental & Hospital Equipment & Supplies

Patient Square Capital to acquire Patterson Companies, Inc.

Announced Dec 11, 2024 · Closed Apr 17, 2025

Deal value$4.10BEV $3.06B
Premium36.0%To unaffected price
EV / Adj. EBITDA9.2x0.5x EV / Revenue
ConsiderationAll cash$31.35 per share

Transaction

Acquirer
Patient Square Capital
Target
Patterson Companies, Inc. (PDCO)
Buyer type
Private equity
Offer price per share
$31.35
Enterprise value
$3.06B
Status
Closed Apr 17, 2025

Deal protections

Break fee (target pays)
$111M · 2.7%
Reverse fee (buyer pays)
$222M · 5.4%
Go-shop
No-shop
Financing
Committed · UBS, Citigroup, Wells Fargo

Advisors

To the acquirer
Citigroup, UBS, Wells Fargo
To the target
Guggenheim

Sector context · Healthcare

Comparable deals
92 in the prior 24 months
Premium
36.0% vs. 67.0% sector median
EV / Adj. EBITDA
9.2x vs. 17.1x sector median
Break fee
2.7% vs. 3.5% sector median

Timeline

  1. AnnouncedDec 11, 2024
  2. Proxy filedJan 24, 2025
  3. Definitive proxyFeb 27, 2025
  4. Shareholder voteApr 1, 2025
  5. ClosedApr 17, 2025
Sources
  • DEFA14A (EX-99.1) · Dec 11, 2024
  • 8-K · Dec 11, 2024
  • 8-K (EX-99.1) · Apr 1, 2025

Adj. EBITDA is operating income + D&A + impairment, restructuring, deal costs and stock compensation, less any large gain on a sale, last twelve months, from the target's filings. Calculated by Castle, so it can differ from a bank's adjusted figure.

Prepared with Castle from public SEC EDGAR filings. Figures are extracted automatically; verify against the source documents. Not investment advice.